Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)
Compounded semaglutide and compounded tirzepatide remain legal when prescribed by a licensed provider for an individual patient based on clinical need
EUFOREA is active in this regard with both paediatric and adult guidelines for AR management (168, 169) and suggestions for increased use of AIT in the recent summit paper (170)
Quick Answer: GLP-1 medications do not directly treat cellulite and may produce unpredictable effects on its appearance through weight loss alone
Hormonal fluctuations affect GLP-1 sensitivity across the menstrual cycle
Studies document effects on approximately 31.2% of human genes, representing over 4,000 genes with expression changes of 50% or greater
